Macquarie has maintained an outperform rating on Zydus Life, with a target price of Rs 1,365. Despite an unfavorable ruling in the gCabometyx patent case, the brokerage remains optimistic about Zydus Life’s prospects.
Macquarie has factored in a potential gCabometyx launch in FY27, although it notes that this could face significant delays. The brokerage expects Zydus to generate $300 million in revenue from this product by FY27, with projected earnings of Rs 10 per share for the same period.
The current market price (CMP) for Zydus Life is Rs 1,018.80.
Disclaimer: This article is for informational purposes only and does not provide investment advice. Investors should consult with a financial advisor before making any investment decisions. Neither the publication nor the author holds any responsibility for investment outcomes based on the information provided.
